ascopubs.org

Clinical activity of camizestrant, a next-generation SERD, versus fulvestrant in patients ...

Efficacy analysis of CDK4/6 inhibitors (CDKi) + endocrine therapy (ET) treatment in hormone receptor-positive/HER2-negative (HR+/HER2-) advanced breast cancer (aBC ...